Top Medical News
Roshini Claire Anthony, 31 minutes ago

The addition of the CDK* 4/6 inhibitor ribociclib to endocrine therapy significantly extended overall survival (OS) in premenopausal women with HR+ HER2- advanced breast cancer, as evidenced in the phase III MONALEESA-7** trial.

Pearl Toh, 18 hours ago
Adding apalutamide to androgen-deprivation therapy (ADT) significantly extends radiographic progression-free survival (rPFS) and overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC) compared with ADT alone, the TITAN* study shows.
22 hours ago
Immunosuppressed patients are at increased risk for postoperative complications, such as surgical site infection and wound dehiscence, following Mohs micrographic surgery (MMS) due to solid organ transplant and immunosuppressive therapy use, according to a new study.
Yesterday
New drug applications approved by US FDA as of 01 - 15 June 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date. 
Roshini Claire Anthony, Yesterday

Gentamicin, while not as effective as ceftriaxone in clearing gonorrhoea infection, may be a suitable alternative treatment for patients who are intolerant or resistant to ceftriaxone, according to the G-ToG study.

Yesterday
Use of antipsychotic drugs (APDs) in survivors of aneurysmal subarachnoid haemorrhage (aSAH) correlates with the extent of brain injury from aSAH, such that APD exposure is minimal in the absence of significant brain injury, a study has found.
Yesterday
Population pharmacokinetics accurately predicts the empiric dose frequency of vancomycin in patients with acute brain injury, as shown by the small clinical difference in population and patient-specific elimination rate constants, according to a new study.
Special Reports
14 May 2019
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).
03 May 2019
At a Boehringer Ingelheim-sponsored symposium, held in conjunction with the joint 12th International Diabetes Federation Western PacificRegion Congress & 10th Asian Association for the Study of Diabetes Scientific Meeting in Kuala Lumpur, two prominent speakers discussed therapidly evolving treatment landscape for diabetes, focusing on the implications of heart failure (HF) and chronic kidney disease (CKD) in thediabetes continuum.
29 Mar 2019
Dapagliflozin 5 mg and 10 mg FC tab
Dr. Jeffrey Ross, Dr. Rohit Lal, Prof. Alwin Krämer, Dr. Rebecca Dent, Prof. Rafal Dziadziuszko, 24 Jan 2019
Comprehensive genomic profiling (CGP) has emerged as a key driving force behind personalized cancer care. With the wealth of data available with CGP, medical oncologists now have in their armamentarium a tool that could enable them to provide patients with the optimum treatment. At a Roche Foundation Medicine-sponsored symposium held at the 2018 European Society of Medical Oncology (ESMO) Congress in Munich, Germany, a panel of experts reviewed key data on CGP, with a focus on the treatment of advanced cancers.
Dr. Choo Gim Hooi, Assoc Prof. Pattarapong Makarawate, Dr. Krisada Sastravaha, 17 Dec 2018
Coronary artery disease (CAD) is a leading cause of mortality and morbidity globally and its burden is expected to increase due to the rising prevalence of risk factors such as hypertension, diabetes, and dyslipidaemia. In conjunction with the 23rd ASEAN Federation of Cardiology Congress held in Bangkok, Thailand, Menarini organized a lunch symposium and product theatre to discuss the significance of optimal medical therapy (OMT) in the management of stable CAD, with a focus on the role of ranolazine (Ranexa®).
Rachel Soon, 12 Dec 2018

MIMS Pharmacist presents an overview of superoxide dismutase (SOD) and its role in resisting the effects of oxidative stress and aging.

01 Nov 2018
The prevalence of allergic diseases in the Asia-Pacific region is expected to rise over the next 20 years, driven by rapid economic development and urbanization. Allergic diseases have high socioeconomic impact by impairing productivity and quality of life, and the impact may be greater in Asia-Pacific than in Europe due to the presence and predominance of perennial allergens.
Conference Reports
Pearl Toh, 15 Jun 2019
Adding apalutamide to androgen-deprivation therapy (ADT) significantly extends radiographic progression-free survival (rPFS) and overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC) compared with ADT alone, the TITAN* study shows.
Audrey Abella, 14 Jun 2019
The taxane-based TPEx regimen demonstrated encouraging overall survival (OS) benefit for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) compared with the fluorouracil (5FU)-based EXTREME regimen, according to the results of the TPExtreme* trial presented at ASCO 2019.
Pearl Toh, 13 Jun 2019

Pembrolizumab is noninferior to standard chemotherapy for overall survival (OS) in advanced gastric or gastroesophageal junction (G/GEJ) cancer in the first-line setting, thus providing a potential alternative treatment option for patients with G/GEJ, according to the KEYNOTE-062 study presented at ASCO 2019.

Roshini Claire Anthony, 13 Jun 2019

Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.

Roshini Claire Anthony, 12 Jun 2019

Women with platinum-sensitive ovarian cancer with germline BRCA mutations who relapsed after previously receiving 2 lines of chemotherapy demonstrated better objective response rates (ORRs) and progression-free survival (PFS) following treatment with olaparib than platinum-based chemotherapy, according to results of the SOLO3* trial.

Pearl Toh, 11 Jun 2019
The novel antibody-drug conjugate enfortumab vedotin showed promising clinical activity in patients with advanced and metastatic urothelial cancer for whom there is a high unmet need, according to the EV-201 study presented at the ASCO 2019 Meeting.
Roshini Claire Anthony, 11 Jun 2019

The reduced mortality/morbidity benefit previously demonstrated with selexipag in patients with pulmonary arterial hypertension (PAH) may be more pronounced when treatment is initiated soon after diagnosis, according to results of a post hoc analysis of the GRIPHON* study presented as a poster at ATS 2019.

CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download